Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Breast Cancer × pyrotinib × 90 days × Clear all

Status

Not yet recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 6 HER2-positive Early Breast Cancer 1 HER2-positive Breast Cancer 1

Interventions

pertuzumab 2 Trastuzumab 2 tucatinib 1 pyrotinib 1 Paclitaxel 1 Fluorodeoxyglucose F18 1 Docetaxel 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07470203 2026-03-13

Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer

Peking University Cancer Hospital & Institute

Not yet recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡